Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial

Next Previous
Trial Profile

Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 18 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide (Primary) ; Ifosfamide (Primary) ; Rivoceranib (Primary)
  • Indications Osteosarcoma
  • Focus Therapeutic Use
  • Acronyms AIEO

Most Recent Events

  • 11 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2026.
  • 11 May 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2026.
  • 11 May 2024 Status changed from recruiting to suspended for trying another trial with randomized design.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top